Our latest research paper, published in Laboratory Investigation, reports the findings of a global ring study carried out across 27 labs worldwide, designed and managed by Diaceutics and in partnership with UK NEQAS.
As part of this study, we assessed the reproducibility and comparability of 3 CLDN18 antibodies (Ventana, LSBio, and Novus) stained on 3 IHC-staining platforms (Ventana, Dako, and Leica).
The study demonstrated the reliability of IHC testing for CLDN18 expression in gastric tumor samples when using commercially available platforms with an appropriate methodology and primary antibody selection.
